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Abstract
The periplasm provides a strongly oxidizing environment; however, periplasmic expression of proteins with
disulfide bonds is often inefficient. Here, we used two different tripartite fusion systems to perform in vivo
selections for mutants of the model protein bovine pancreatic trypsin inhibitor (BPTI) with the aim of enhancing
its expression in Escherichia coli. This trypsin inhibitor contains three disulfides that contribute to its extreme
stability and protease resistance. The mutants we isolated for increased expression appear to act by eliminating
or destabilizing the Cys14-Cys38 disulfide in BPTI. In doing so, they are expected to reduce or eliminate kinetic
traps that exist within the well characterized in vitro folding pathway of BPTI. These results suggest that
elimination or destabilization of a disulfide bond whose formation is problematic in vitro can enhance in vivo
protein folding. The use of these in vivo selections may prove a valuable way to identify and eliminate disulfides
and other rate-limiting steps in the folding of proteins, including those proteins whose in vitro folding pathways
are unknown. Antioxid. Redox Signal. 14, 973–984.
Introduction
Disulfide bonds are critical posttranslational modifica-tions that regulate the folding and stability of proteins.
The activities of many extracellular and pharmaceutically
relevant proteins such as insulin and the tissue plasminogen
activator rely on the formation of their correct disulfide bond
pattern (22). Escherichia coli is a preferred host for heter-
ologous protein expression due to its simple and inexpensive
cultivation, ease of genetic manipulation, and the compre-
hensive understanding of its genetics (40). Because of its
ability to form disulfide bonds, the oxidizing environment of
the bacterial periplasm in particular is often the compartment
of choice for the expression of disulfide bond-containing
proteins (3).
Frustratingly, despite the extremely high native-state sta-
bility of proteins with multiple disulfide bonds (34), heter-
ologous proteins with complex disulfide bond patterns often
express very poorly in E. coli (32). One example is the bovine
pancreatic trypsin inhibitor (BPTI) (31), which in its mature
form contains three nonconsecutive disulfide bonds involving
all of its six cysteines. Fully oxidized, native BPTI has a
melting temperature of over 1008C (36). However, the protein
folds poorly in bacteria, resulting in very low expression
yields (31). The in vitro folding pathway of BPTI is probably
the most intensively studied of all proteins and is dominated
by the formation and isomerization of its disulfide bonds (1,
16, 45). Conversely, much less is known about the in vivo
folding of BPTI, especially in heterologous systems (31–33). It
is still not clear whether the folding challenges BPTI faces
in vitro are also responsible for its relatively low expression in
heterologous systems compared to that of other proteins (31).
In this study, we utilized two independent genetic systems
to select for BPTI variants that exhibit improved expression
and folding properties in the E. coli periplasm. The nature of
the BPTI variants obtained supports the theory that destabili-
zation or elimination of the native disulfide bond Cys14-Cys38
allows for amore productive route of folding toward the native
state in vivo. The use of in vivo selectionsmay therefore prove to
be a valuable way to identify and circumvent critical rate-
limiting steps in the in vivo folding of proteins, including those
proteins whose in vitro folding pathways are unknown.
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Materials and Methods
Cloning of phages for the protein stability
increased by directed evolution system
fd phage derivatives were grown on XL1-Blue E. coli cells
(Stratagene, La Jolla, CA). For cloning and sequencing of
phage DNA, the replicative form was prepared using a
Qiagen Miniprep Kit (Qiagen, La Jolla, CA). To construct tri-
partite fusions within the g3p protein of fd, a derivative of fd
phage called fdP213 was used. This variant carries the g3p
protein stabilizing mutations T13I, T101I, Q129H, D209Y, and
P213G (29). The gene for BPTI was amplified from pTI103
plasmid (15) using the primers 50-TAATTAGGGCCCGG
CCTGACTTCTGC-30 and 50-GCTAATAGGGCCCCACCAC
AGGTCCTCATGCA-30. These primers introduced ApaI sites
at the 50 and 30 ends of the gene for mature portion of BPTI,
enabling its insertion into the ApaI site that had been previ-
ously engineered into the g3p gene of fd phage by Krebber et
al. (25). This allowed the in-frame cloning of BPTI into the g3p
gene with no change in the amino acid sequence of BPTI,
resulting in the phage PHSG7. It also placed BPTI between the
N- and the C-terminal domains of the g3p protein. Inverted
inserts were selected against because they created stop codons
in g3p, preventing phage infectivity. The resulting fusion
protein is referred to as ‘‘g3p0-BPTI WT-0g3p.’’
Directed evolution of BPTI in the phage system
Mutagenesis of the BPTI gene was performed according to
the GeneMorph II EZClone domain mutagenesis kit (Strata-
gene) with some minor modifications. Briefly, the BPTI se-
quence was amplified from pHSG7 DNA in an error-prone
polymerase chain reaction (PCR) using the Mutazyme II en-
zyme mix and primers 50-CTGTCAATGCTCCGTCCGG
GGCC-30 and 50-GTACCAGAAGCCATGGCCGGCTG-30,
which annealed up- and downstream of the BPTI gene. The
PCR was performed as recommended by Stratagene, except
that the annealing temperature was 558C and the elongation
timewas 1min. The resulting pool ofmutagenized BPTI genes
was then used to perform a second, nonmutagenic PCR on
pHSG7 DNA, according to the GeneMorph II protocol, to
complete the synthesis of the fd phage. After digestion with
DpnI (New England Biolabs, Beverly, MA), the remaining
PCR product was precipitated. The resuspended DNA pellet
was transformed into XL1-Blue cells, and the cultures were
grown in LB for 14 h at 378C. This simple outgrowth served
as a growth competition selection that allowed the most in-
fectious phage to outgrow less infectious phages in the cul-
ture. This protocol was designed to enable the selection of
mutations within the BPTI gene that conferred a growth
advantage to the g3p-BPTI tripartite fusion containing fd
phage. Subsequently, the cultures were pelleted and the
phage containing supernatant was plated using 0.7% top
agar LB in different dilutions. Plaques larger than those of
the unmutagenized pHSG7 phage (which generated tiny,
almost invisible plaques) were picked and used to re-infect
10ml of an overnight culture of XL1-Blue cells. These cells
were again grown for 14 h to grow up the large plaque phage
clones. After harvesting, the phage titer [plaque forming
units (pfu)=ml] was determined, and the sequence of the
BPTI gene determined from the isolated replicative form of
the phage.
Directed evolution of BPTI in the b-lactamase system
To construct a tripartite fusion between BPTI WT and b-
lactamase, the gene for BPTI was first PCR-amplified from
pT1103 using primers 50-CTGTCAATGCTCCGTCCGGG
GCC-30 and 50-GTACCAGAAGCCATGGCCGGCTG-30 and
then cloned into the PfoI site within the b-lactamase gene in
pBR322*link to obtain pBR322*link-BPTI. The resulting fusion
protein is referred to as bla0-BPTIWT-0bla. The BPTI gene was
then randomly mutagenized, and clones that showed an en-
hanced resistance to penicillin V (Pen V) or ampicillin were
isolated, and the minimal inhibitory concentration (MIC) of
antibiotic necessary to inhibit their growth was determined as
previously described (13). Additional specific mutations in
BPTI were generated using the QuikChange Site-Directed
Mutagenesis Kit (Qiagen).
Determination of expression levels
Whole cell extracts were prepared as previously described
(13).
For the separation of the soluble and insoluble fractions,
mid-log-phase cells were pelleted (13,000 g, 48C, 5min) and
adjusted to OD600 nm¼ 7 in lysis buffer (10mM Tris, 2mM
EDTA, 1mg=ml lysozyme, and protease inhibitor). One
hundred microliters of this mixture was subjected to 10
freeze–thaw cycles and the soluble and the insoluble fractions
were separated by centrifugation (13,000 g, 48C, 10min). The
supernatant after centrifugation was the soluble fraction. The
pellet (insoluble fraction) was resuspended in a total volume
of 100ml resuspension buffer (3.2mM Na2HPO4, 0.5mM
KH2PO4, 1.3mM KCl, 135mM NaCl, 2mM EDTA, and pro-
tease inhibitor, pH 7.4).
For the preparation of periplasmic extracts, a volume of
mid-log-phase cells corresponding to OD600 nm¼ 7 was
pelleted (13,000 g, 48C, 10min) and resuspended in 70 ml
osmotic shock buffer (0.2M Tris pH 8, 0.5M sucrose, 1 mM
EDTA). After incubation on ice for 30min, the supernatant
(periplasmic extract) and the pellet (cytoplasmatic frac-
tion) were separated by centrifugation (13,000 g, 48C,
10min).
To obtain samples in which bla0-link-BPTI-0bla would still
contain its signal sequence, mid-log phase cells expressing
bla0-link-BPTI-0bla under arabinose control were induced
with 2% arabinose. After 2min, the cells were treated with
0.08% sodium azide, incubated for another 18min, and
whole cell extracts were prepared as described above. For
the expression of BPTI in the absence of b-lactamase, BPTI
was expressed from pET11a (New England Biolabs) under a
T7 promoter. Protein production was induced with 5 mM
IPTG.
Protein samples were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and Western
blot analysis. Proteins were detected using a monoclonal
rabbit antibody raised against TEM1-b-lactamase (Milli-
pore, Billerica, MA) or reduced BPTI (generous gift from
George Georgiou) as a primary and HRP-goat anti-rabbit
IgG (Thermo Scientific, Waltham, MA) as a secondary
antibody. Various dilutions of the protein samples for
constructs containingWT BPTI and the BPTI variants were
loaded on the gel. For each dilution, the ratio of band in-
tensities for the mutant BPTI and WT BPTI was deter-
mined and averaged.
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Results
To select for variants of BPTI that show enhanced expres-
sion and folding in the bacterial periplasm, we employed two
independent tripartite fusion approaches that link the in vivo
folding of BPTI to the activity of a reporter protein. The first
approach was a modification of the protein stability increased
by directed evolution (PROSIDE) technique (29); the second
approach was the split b-lactamase system developed in our
lab (13). In the PROSIDE approach, a guest protein is inserted
between the N- and C-terminal domains of the g3p capsid
protein of the fd phage (Fig. 1A). Both domains must remain
covalently linked for g3p to be functional and confer phage
infectivity. If the inserted protein is poorly folded or unstable,
it becomes proteolytically sensitive. Degradation of the in-
serted protein will lead to a separation of the N- and C-
terminal domains and a loss of infectivity. However, if the
inserted guest protein folds well, the two domains of g3p
remain covalently linked, and the phage carrying the fusion
protein is infectious. This method therefore directly links the
in vitro stability of the guest protein with phage infectivity.
Improved folding efficiency of the guest protein in the peri-
plasm should result in a higher infectivity of the phage, re-
sulting in larger plaque sizes and increased phage titers.
In the b-lactamase system, the guest protein is inserted
between theN- andC-terminal halves of TEM1-b-lactamase, a
periplasmic enzyme that confers resistance to b-lactam anti-
biotics (13) (Fig. 1B). We used this technique previously to
monitor the in vivo stability of a variety of different proteins
and to identify variants with improved thermodynamic and
kinetic stability by selecting for increased levels of antibiotic
resistance (13). As in the PROSIDE system, poor folding of the
guest protein makes it susceptible to proteolytic degradation,
leading to a separation of the two halves of the reporter pro-
tein. Bacteria expressing such a construct are therefore sensi-
tive to antibiotic stress. A well-folded guest protein, however,
ensures that the fusion remains intact, thereby leading to high
levels of antibiotic resistance.
Selecting for BPTI variants that lead
to increased infectivity in the PROSIDE system
The phage system links the proteolytic stability of a guest
protein to phage infectivity and therefore to the rate of phage
amplification. Insertion ofWT BPTI into the protein g3p of the
fd phage (referred to as ‘‘g3p0-BPTI WT-0g3p’’) resulted in a
dramatic decrease in phage titer (from*1011 pfu=ml for WT
fd phage to*106 pfu=ml for g3p0-BPTIWT-0g3p, Table 1). This
result is consistent with the poor in vivo folding and expression
of BPTI noted previously (33). We reasoned that by muta-
genizing the BPTI portion of the fusion and selecting for var-
iants that show improved phage growth, we should be able to
identifymutantswith improved in vivo expression and folding
properties. About 22 independent mutagenesis reactions
yielded a total of 42 phage variants that resulted in increased
plaque sizes and higher phage titers. Sequence analysis re-
vealed two classes of fd variants that improved phage growth.
The first class consisted of 25 independent deletion variants in
which all or nearly all of the BPTI encoding sequence was
selectively removed from the g3p gene. These deletion variants
all showed titers and plaque sizes comparable to the original
WT phage (data not shown). The remaining 17 phage vari-
ants had acquired single or multiple mutations in the BPTI
sequence and showed increased plaque size and titer com-
pared to g3p0-BPTI WT-0g3p (listed in Table 1).
For the two BPTI variants with single mutations (F33L and
G12D), it is clear that the single mutation is sufficient for the
enhanced growth phenotype. The vast majority of BPTI var-
iants isolated, however, contained multiple amino acid sub-
stitutions, complicating interpretation. Many of the residues
FIG. 1. Directed evolution of proteins using the modified
protein stability increased by directed evolution and the b-
lactamase tripartite fusion systems. The test protein BPTI
(shown in orange) is inserted into either the minor coat
protein of the fd phage, g3p, (A) or b-lactamase (B), creating
a tripartite fusion. (A) During phage replication in Escherichia
coli, g3p is first synthesized as an integral membrane protein
(shown) before it is assembled into the phage coat (not
shown). The N-terminal domain of g3p carries the recogni-
tion site for the bacterial receptors the phage binds to during
infection, and the C-terminal domain anchors g3p into the
phage coat. Therefore, both domains must remain covalently
linked for g3p to be functional and maintain phage infec-
tivity. (B) b-lactamase (bla) is a periplasmic enzyme that
inactivates b-lactam antibiotics. The ability of the tripartite
fusions to confer phage infectivity (A) or resistance to anti-
biotics (B) is strongly dependent on the in vivo stability of the
guest protein that is inserted into the reporter protein. If the
test protein is stable and folded properly, the two halves of
the reporter protein remain covalently linked and confer
activity (left). If the inserted protein is not properly folded or
unstable, it is prone to degradation by periplasmic proteases
(depicted as scissors) and is likely to be degraded (right).
This leads to a separation of the N- and C-terminal frag-
ments of g3p=b-lactamase, resulting in a decreased phage
titer=antibiotic resistance (13). BPTI, bovine pancreatic tryp-
sin inhibitor. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of
this article at www.liebertonline.com=ars).
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substituted were isolated on multiple occasions; 12 of the 33
point mutations identified affected residues that were found
to be altered in multiple, independent mutagenesis reactions
(shown bold in Table 1). We reasoned that the more often a
residue was independently replaced in different BPTI vari-
ants, themore likely that alteration of this residue is important
for robust growth of the phage expressing the g3p-BPTI var-
iant. Among the isolated BPTI variants, six residues (F4, R17,
I18, V34, R39, and R42) were independently found to be
mutated twice, four (A16, Y35, A40, and S47) were mutated
three times, and two (C14 and C38) were mutated four times.
It is striking that of the 15 BPTI variants with multiple amino
acid substitutions, the four variants exhibiting the largest in-
crease in phage titer all eradicate the Cys14-Cys38 disulfide by
eliminating both of the involved cysteines. Remarkably, seven
of the substitutions that do not affect the cysteines are exactly
the same as substitutions that have previously been found to
destabilize Cys14-Cys38 in vitro (underlined in Table 1) (17).
To confirm that these amino acid substitutions are, on their
own, sufficient to increase phage titers compared to phage
containingWTBPTI,we attempted to construct the individual
mutations in the phage system by site-specific mutagenesis.
However, the very strong growth disadvantage conferred
upon fd by g3p fusions containingWT BPTI and the resulting
low titer greatly decreased the amount of DNA that could be
isolated from the WT BPTI construct, making site-specific
mutagensis very difficult. When high yields of DNA were
obtained, we observed that it was often the result of the
spontaneous evolution of phage containing deletions or other
mutations within BPTI. The underlying basis of this problem
is unfortunately exactly the same as the basis of the genetic
selection; namely, the coupling of the growth of the phage to
the folding of the test protein.
Selecting for BPTI variants that lead to increased
antibiotic resistance in the b-lactamase system
To circumvent the problem of lowDNA levels and frequent
excisions of the BPTI gene from the phage genome, we de-
cided to establish growth conditions in which the folding of
the inserted protein could be selectively uncoupled from the
growth of strains containing the selectable marker. This was
not possible for the g3p tripartite fusions because g3p is re-
quired for phage propagation and consequently phage DNA
amplification. We therefore employed a second genetic se-
lection system, the b-lactamase system. Here, the tripartite
fusion is expressed from a bacterial plasmid that also encodes
for an additional selectable marker, tetracycline resistance.
Growing cells containing this plasmid in tetracycline allows
for an easy amplification and manipulation of plasmid DNA
without any requirement for efficient folding of the tripartite
b-lactamase protein. The b-lactamase system further provides
a very reproducible readout for the relative level of antibiotic
resistance conferred by different tripartite fusions (13).
The construction of a plasmid expressing a tripartite fusion
between BPTI WT and b-lactamase (referred to as ‘‘bla0-BPTI
WT-0bla’’) and the determination of the resulting level of an-
tibiotic resistance is described in Materials and Methods.
Antibiotic resistance is given as the MIC that prevents cell
growth. The level of resistance caused by a given BPTImutant
is normalized to the level of resistance conferred by bla0-BPTI
WT-0bla. The insertion of BPTI into b-lactamase resulted in a
massive drop in antibiotic resistance compared to cells ex-
pressing WT b-lactamase, similar to the drop in phage infec-
tivity that accompanied the insertion of BPTI into g3p (Fig. 2).
As with the phage selection, we randomly mutagenized the
BPTI portion of the tripartite fusion gene; however, in this
case, we selected for increased antibiotic resistance to identify
BPTI variants that show enhanced protein levels and folding
in the periplasm. Using this approach, we isolated 13 point
variants and 1 triple variant (P13S C14Y G28R) that showed
increased MIC values compared to cells expressing bla0-BPTI
WT-0bla (Table 2). We also constructed point variants P13S
and G28R in the BPTI WT background by site-specific muta-
genesis, and they also showed increased levels of antibiotic
resistance. Variants isolated with the b-lactamase system that
eliminate or destabilize the Cys14-Cys38 disulfide bond are
underlined in Table 2.
For the two point mutations that led to the largest increase
inMIC, BPTI G28WandK26M,we also tested the steady-state
protein levels in the periplasm. These measurements were
made both for BPTIwhen it was part of the tripartite fusion, as
well as the isolated BPTI protein expressed on its own in the
absence of b-lactamase. In both these contexts the protein
levels of BPTI G28W and K26M in whole cell extracts were
Table 1. Phage Titers for Bovine Pancreatic Trypsin
Inhibitor Variants Obtained with the Phage System
g3p0-BPTI-0g3p variant Relative phage growth
WT fd phage þþþþþ
BPTI WT þ=
G12D þþþ
F33L þþþ
C14S, C38S þþþþþ
C14R, C38Y, P2S, D3F þþþþ
C14Y, C38W, A40D þþþþ
C14Y, C38Y, R42S, K46M þþþþ
Y35N, A40S, K41N þþþ
R17G, G37N þþþ
A16T, I18N, S47N þþþ
A16N, V34E þþþ
I18S, A40S þþþ
L6Q, R17S þþþ
V34E, S47N þþþ
F4L*, A16T, R39N þþþ
F4L*, K26N, R39S þþþ
P13S, Y35G þþþ
Y35N, G36D, R42S, S47N þþþ
Insertion of WT BPTI into the g3p encoding sequence of the phage
decreased the phage titer from *1011 pfu=ml (þþþþþ) to 106
pfu=ml (þ=). Titers varied significantly from experiment to
experiment; values shown are the average of 3 experi-
ments.þþþþcorresponds roughly to a phage titer of 1010
pfu=ml,þþþroughly to 109 pfu=ml. Residues in bold were found
to be substituted in multiple independent mutagenesis reactions. In
most of these cases, the chemical nature of the amino acid
substitution was the same. Underlined are the BPTI exact amino
acid substitutions that were previously found to selectively reduce
the Cys14-Cys38 disulfide upon adding DTT in vitro (2, 18) and=or
are known to destabilize this particular disulfide bond in vitro (17).
Dotted underlined variants eliminate the Cys14-Cys38 disulfide
bond completely. Variants that have been shown to decrease the
accumulation of kinetic traps in the folding pathway of BPTI in vitro
are marked with * (50).
BPTI, bovine pancreatic trypsin inhibitor; DTT, dithiothreitol; pfu,
plaque forming unit; WT, wild-type.
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significantly increased compared to the corresponding WT
constructs (2.5 0.2-fold for BPTI G28Wand 2.8 0.3-fold for
K26M in the fusion context, compared to the protein level of
bla-BPTI WT-bla; 1.5 0.1-fold for BPTI G28W and 1.7 0.2-
fold for K26M in the isolated protein in the absence of the
fusion, compared to the protein level of WT BPTI itself. This
suggests that the b-lactamase system works well for the se-
lection of protein variants with increased expression in E. coli.
Destabilization of Cys14-Cys38 in vitro correlates
with increased levels of antibiotic resistance
in the b-lactamase system in vivo
Because disulfide bonds act to stabilize proteins, we were
initially surprised that the elimination or destablization of
Cys14-Cys38 in BPTI was actually reflected in improved
phenotypes in the phage system.Wewere therefore interested
in whether the degree of destabilization of the Cys14-Cys38
disulfide as determined in vitro would correlate with in-
creased protein stability in vivo as reflected by improved
phenotypes in the tripartite fusion systems. In contrast to the
phage system, which was characterized by a rather high
propensity for recombination events that lead to the elimi-
nation of the protein inserted into g3p and phage titers that
varied significantly from experiment to experiment, the b-
lactamase system is genetically very stable and has been
shown to provide a very reproducible phenotype for a variety
of insert proteins (13). We introduced four of the amino acid
substitutions that were obtained in the phage selection as
point mutations into the bla0-BPTI WT-0bla background, and
one mutant, Y35L, that was derived from the literature (17).
All five BPTI variants are known to destabilize this disulfide
bond in vitro (17). Remarkably, the extent of thermodynamic
destabilization of Cys14-C38 caused by a given point muta-
tion in vitro correlated well with the level of antibiotic resis-
tance in the b-lactamase system (Fig. 3). Consistent with these
FIG. 2. Insertion of BPTI into b-lactamase leads to a
massive drop in antibiotic resistance compared to cells
expressing the unmodified enzyme. Mid-log phase cells of
E. coli MG1655 DampC expressing TEM1-b-lactamase (bla
WT) or TEM1-b-lactamase fused with WT BPTI (bla0-BPTI
WT-0bla), respectively, were normalized to OD600 nm¼ 1.
Serial dilutions of cultures from 100 to 105 were spotted on
LB plates containing different concentrations of ampicillin.
After 18 h of incubation at 378C, growth or no growth for
each dilution for each ampicillin concentration was deter-
mined. WT, wild-type.
Table 2. Minimal Inhibitory Concentration Values for Bovine Pancreatic Trypsin
Inhibitor Variants Obtained with the b-Lactamase System
BPTI variants obtained in the selection BPTI variants constructed via site-directed mutagenesis
bla0-BPTI-0bla MIC SD bla0-BPTI-0bla MIC SD
bla WT 2.07 0.07 A16T 0.98 0.02
BPTI WT 1.00 0.00 F33L 0.94 0.06
N24H 1.07 0.06 Y35N 1.01 0.08
P13Sa 1.10 0.02 Y35L 1.07 0.01
I18L 1.10 0.02 N24A 1.08 0.08
I19F 1.17 0.01 Y35G 1.12 0.04
Y10N 1.23 0.02 Y23L 1.18 0.01
Q31K 1.23 0.01
A25V 1.23 0.05 [14–38] 0.13 0.02
Q31R 1.25 0.01 [30–51] 0.90 0.03
P13L 1.36 0.04 [5–55] 1.46 0.03
G28Ra 1.37 0.01
C14W 1.43 0.06 [5–55] [14–38]b 0.74 0.02
N24K 1.50 0.09 [14–38] [30–51]b 1.10 0.03
K26M 1.88 0.09 [5–55] [30–51]b 1.70 0.06
G28W 1.91 0.10
P13S C14Y G28Ra 1.35 0.08
The relative level of antibiotic resistance of cells expressing different bla0-BPTI-0bla variants is given as the minimal inhibitory concentration
(MIC) that prevents cell growth (see the Materials and Methods section). Residues in bold were substituted more than once in independent
mutagenesis reactions. In most of these cases, the chemical nature of the amino acid substitution was the same. Residues underlined were
identified in a screen for DTT-sensitive mutants as single point mutations or are known to destabilize the Cys14-Cys38 disulfide in vitro (2, 17,
50). The dotted underlined variants prevent formation of Cys14-Cys38.
aP13S and G28R were selected as part of a triple mutant (P13S C14Y G28R) and subsequently constructed as single point mutations via site-
directed mutagenesis.
bRelative protein levels of [5–55] [14–38], [14–38] [30–51], and [5–55] [30–51] in the b-lactamase system were 0.9 0.1, 1.2 0.2, and
1.6 0.1, respectively.
SD, standard deviation.
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findings, complete removal of the Cys14-Cys38 disulfide
bond leads to an even higher MIC (Fig. 3, open diamonds).
Importantly, the elimination of the Cys14-Cys38 disulfide
bond increases the protein level of BPTI in E. coli both when it
is part of the tripartite fusion as well as when BPTI is ex-
pressed on its own (1.6 0.1-fold increase in protein level
relative to bla0-BPTI WT-0bla in presence of b-lactamase and
2.3 0.2-fold increase in protein level relative to BPTI WT in
absence of b-lactamase, respectively). These results fit nicely
with a previous observation that the elimination of this dis-
ulfide by serine substitutions leads to a 7-fold increase in the
expression level of BPTI in the E. coli periplasm (31).
The stabilities of single disulfide-bonded BPTI
species in vitro correlate with the level of antibiotic
resistance in the b-lactamase system in vivo
Because the b-lactamase system has been shown to be a
good readout for the in vivo stability of a variety of proteins
(13), we decided to use it to assess which of the different
intermediates that accumulate in BPTI’s folding pathway
in vitro might be especially problematic for BPTI’s folding
in vivo. Traditionally, much information about the folding
pathway of BPTI has been obtained by studying the proper-
ties of analogs of folding intermediates (11) in which partic-
ular pairs of cysteines were chemically blocked or replaced
with other amino acids, especially serine (6). To create three
BPTI variants that can only form a single native disulfide
bond, we used site-directed mutagenesis to replace all but
one cysteine pair with serines. We list the disulfide mutants
we constructed and define our nomenclature in Table 3.
Among the single disulfide-bonded species containing native
disulfides, BPTI [5–55] has the most native-like conformation
in vitro, whereas [14–38] has the least (26, 41). Introduction of
[5–55] into the b-lactamase system resulted in the highest
MIC, whereas introduction of the least structured and least
stable species ([14–38]) resulted in the lowest MIC, suggesting
that the latter intermediate does not form a stable conforma-
tion in the bacterial periplasm (Fig. 4A). These results indicate
that, for single disulfide-bonded species of BPTI, the extent of
native structure in vitro is correlated to the MIC in vivo.
Consistently, the levels of antibiotic resistance for BPTI [5–55],
[14–38], and [30–51] correlate very well with the contribution
of the particular disulfide bond to the stability of the folded
conformation, as reflected by the effective concentration of the
disulfide bond in the native state (7, 23) (Fig. 4B). Interest-
ingly, there is an inverse correlation between the MIC and the
tendency of a disulfide to form in reduced BPTI: the higher the
conformational preference for formation of a particular native
disulfide in the reduced state, the lower the MIC of the BPTI
variant that can only form this particular disulfide (Fig. 4C).
An inverse correlation was also found between the MIC and
the reactivity of the involved cysteines, with higher reactivites
Table 3. Nomenclature for Bovine Pancreatic Trypsin Inhibitor Variants Used in This Study
BPTI species Alternative name Contains disulfide bond(s)
Corresponds to BPTI variant
in the b-lactamase system
[5–55] – Cys5-Cys55 C14S C30S C38S C51S
[14–38] – Cys14-Cys38 C5S C30S C51S C55S
[30–51] – Cys30-Cys51 C5S C14S C38S C55S
[5–55; 14–38] – Cys5-Cys55 and Cys14-Cys38 C30S C51S
[5–55; 30–51] – Cys5-Cys55 and Cys30-Cys51 C14S C38S
[14–38; 30–51] – Cys14-Cys38 and Cys30-Cys51 C5S C55S
[5–55; 14–38; 30–51] Wild-type Cys5-Cys55, Cys14-Cys38 and Cys30-Cys51
CysX-CysY refers to a disulfide bond formed between cysteine residue X and cysteine residue Y. BPTI variants representing folding
intermediates found in vitro were obtained by substituting cysteines not involved in disulfide bond formation with serines.
FIG. 3. Increased destabilization of the Cys14-Cys38 dis-
ulfide bond in vitro correlates with increased antibiotic
resistance in the b-lactamase system in vivo. Different
variants of BPTI were inserted into b-lactamase via flexible
linkers. The level of antibiotic resistance for cells expressing
the corresponding fusion constructs was determined as de-
scribed in the Materials and Methods section. BPTI variants
containing single amino acid substitutions that were either
identified in the phage selection (A16T, F33L, Y35N, and
Y35G) or obtained from the literature (Y35L) are indicated
with filled diamonds (17). The relative level of antibiotic re-
sistance (indicated by MIC) compared to a tripartite fusion
containing BPTI WT in vivo is plotted against the thermo-
dynamic destabilization DDG of the Cys14-Cys38 disulfide
bond in the mutant proteins as determined in vitro (DDG¼R
T ln[Ceff (WT)=Ceff(mut)], where Ceff (WT) and Ceff (mut) are
the effective concentrations of the Cys14-Cys38 disulfide
bond in WT BPTI or the mutant proteins, respectively) (17).
Stability values for a BPTI species in which the formation of
Cys14-Cys38 was prevented by either carboxymethylation or
carboxyamidomethylation were taken from Schwarz et al.
(36) and plotted against the level of resistance conferred by
bla0-BPTI C14S C38S-0bla. These latter variants are proteins
with chemical side chain modifications rather than muta-
tions, and their thermodynamic destabilization values were
determined using a different methodology. Therefore, their
absolute values may not be precisely comparable to the
single amino acid substitutions; they are shown as open di-
amonds. The R2 value for the single point variants (filled
diamonds) is 0.89, and the R2 for the complete data set is 0.91.
Data are expressed as mean values SD. MIC, minimal
inhibitory concentration; SD, standard deviation.
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resulting in lower MICs (data not shown) (9). Further, we
observed that a single disulfide-bonded variant of BPTI, [5–
55], which is substantially less stable than the native protein
(43), exhibits a higher MIC than WT BPTI in the b-lactamase
system (Table 2), and this is testimony to the severe folding
problems WT BPTI faces in the periplasm of E. coli.
Because the MIC is a measure of how many molecules are
successfully exported, wewondered if the lowMIC caused by
bla0-BPTI [14–38]-0bla was the result of a preferred formation
of this disulfide in the cytosol, preventing export. bla0-BPTI
[14–38]-0bla showed a protein level in whole cell extracts that
was substantially higher than expected from its MIC value
(protein level was 1.1 0.1, MIC was only 0.13 0.0 com-
pared to bla0-BPTI WT-0bla). Subsequent analysis of soluble=
insoluble and periplasmic=cytosolic fractions of cells expres-
sing bla0-BPTI [14–38]-0bla indicated that the majority of the
protein was periplasmic, but insoluble (Fig. 5). This result is in
stark contrast to that obtained for the rest of the bla0-BPTI-0bla
variants, which showed a very good correlation between level
of antibiotic resistance and steady-state levels of the fusion
proteins in whole cell extracts (Fig. 6). The latter observation is
consistent with previous experiments using the b-lactamase
system, which showed that the level of antibiotic resistance is
a good measure for the relative level of the fusion protein in
the periplasm (13). However, the actual amount of soluble,
periplasmic bla0-BPTI [14–38]0-bla reflected the observed
level of antibiotic resistance for bla0-BPTI [14–38]-0bla very
well (periplasmic level compared to bla0-BPTI WT-0bla was
0.11 0.05).
The b-lactamase system is also suitable
to assess the effect of free cysteines
on the in vivo stability of a protein
During heterologous protein expression in E. coli, the
presence of unpaired cysteines in recombinant, disulfide bond
containing proteins can promote the formation of incorrect
intra- and intermolecular disulfide bonds, leaving the pro-
tein in inactive and aggregation-prone conformations (27).
Elimination of free cysteines via site-directed mutagenesis
has successfully been used to increase the stability, spe-
cific activity, and expression of these proteins and reduce
their aggregation propensity (14, 30). However, since the
FIG. 4. In BPTI variants that can only form a single dis-
ulfide bond, the stability of the disulfide bond in vitro
correlates with the level of antibiotic resistance in the b-
lactamase system in vivo. (A) Three variants of BPTI re-
presenting single disulfide-bonded intermediates ([14–38],
[30–51], or [5–55], respectively) were inserted into b-lacta-
mase via flexible linkers. In all variants, the cysteines not
involved in formation of the disulfide bond indicated were
substituted with serines. Bla WT indicates WT b-lactamase
without any insertions, and BPTI WT refers to the construct
bla-0BPTI WT-0bla. The level of antibiotic resistance (indi-
cated by MIC) for cells expressing the corresponding fusion
constructs was determined as described in the Materials and
Methods section and is normalized to cells expressing bla0-
BPTI WT-0bla. (B) The ‘‘effective concentration’’ of two in-
teracting groups in the native-like conformation can be used
as an expression of the free energy of the intermolecular in-
teraction (23). The higher the effective concentration, the
larger is the contribution of the particular interaction to the
stability of the folded formation. Values for the effective
concentrations were taken from Creighton and Goldenberg
(7). (C) In the reduced state, the kinetic effective concentra-
tion can be used to assess the extent to which two cysteines
are brought into proximity to each other (9). Values for the
effective concentration for the three disulfide bonds indi-
cated were taken from Dadlez and Kim (9). Data are ex-
pressed as mean values SD.
FIG. 5. The majority of BPTI [14–38] detected in whole
cell extracts is periplasmic, but insoluble. Cell fractions
were prepared from E. coli MG1655b DampC cells expressing
bla0-BPTI WT-0bla or bla0-BPTI [14–38]-0bla, respectively, as
described in the Material and Methods section. The tripartite
fusions were detected by Western blot using an anti-b-
lactamase antibody. In cells treated with sodium azide, the Sec
pathway is blocked and the export of the tripartite fusions
prevented (NaN3). Here, tripartite fusion proteins remain in
the cytosol and retain their signal sequence, which is usually
cleaved upon export in the periplasm. Tripartite fusions that
were exported (as detected in the periplasmic extracts [PE],
indicated with peri.) can therefore be distinguished from fu-
sion proteins that were retained in the cytosol (as detected in
the sample treated with NaN3, indicated with cyto.) by their
molecular weight. The blot shows that for both bla0-BPTI WT-
0bla and bla0-BPTI [14-38]-0bla, all fusion protein detected in
whole cell extracts (WC) is located in the periplasm. However,
for bla0-BPTI [14-38]-0bla the amount of soluble protein is
much lower than for bla0-BPTI WT-0bla (compare soluble [SO]
and insoluble fractions [IS]).
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substitution of cysteines has also been shown to decrease
protein stability by reducing hydrophobic interactions or
generating cavities in the protein core (30), the effect of such
mutations is hard to predict and can largely depend on the
amino acid the cysteine is replaced with (21).
WT human granulocyte-colony stimulating factor (hG-
CSF), which forms two natural disulfide bonds and contains
one unpaired cysteine (Cys17), has a high propensity to ag-
gregate, even under native-like conditions (35). This aggre-
gation propensity is significantly decreased when the free
cysteine is eliminated (35). In agreement with this observa-
tion, introduction of hG-CSF C17S into the b-lactamase
system leads to an substantial increase in antibiotic resis-
tance over a range of PenV concentrations compared to WT
hG-CSF (Fig. 7) (13). This suggests that the b-lactamase
technique can be used to identify cysteine mutations that are
beneficial for the expression and in vivo stability of the cor-
responding protein by randomly mutating the proteins
cysteines and simply selecting for increased levels of anti-
biotic resistance.
Discussion
Elimination or destabilization of the Cys14-Cys38
disulfide of BPTI leads to an increased expression
in the bacterial periplasm
Despite the increasing number of studies investigating the
folding and stability of proteins in the living cell (20), the
fundamental question as to what extent in vitro folding ex-
periments reflect the actual folding pathway in vivo has not
been sufficiently answered for many proteins. In this study,
we chose a multi-disulfide-bonded protein that is particularly
poorly expressed in heterologous systems with the aim of
selecting for variants that show improved folding and ex-
pression in the periplasmic space of E. coli. The test protein
BPTI and many of its mutants have already been extensively
characterized in vitro, allowing a direct comparison of mu-
tants described in the literature with variants obtained in our
in vivo selection.
Both genetic selection systems employed in this study were
designed to exclusively identify variants that are successfully
exported to the oxidizing environment of the periplasm, en-
suring that we isolated BPTI variants showing increased
protein levels in the bacterial compartment that would favor
the correct formation of the protein’s disulfide bonds. Strik-
ingly, BPTI variants that resulted in the strongest phenotypes
indicative of improved folding and expression in both selec-
tion systems completely eliminated one of BPTI’s three native
disulfide bonds, Cys14-Cys38. When analyzing our isolated
BPTI variants in which no cysteines were mutated, we further
noticed a high degree of overlap with BPTI variants sensitive
to the reducing agent dithiothreitol (DTT) that were previ-
ously isolated in a screen by Coplen (2). This screen identified
BPTI variants that are able to fold into an active conformation
but, unlike WT BPTI, rapidly lose their protease inhibitory
activity upon addition of DTT and are consequently in-
activated in the presence of trypsin (2, 18). In total, our se-
lections for increased folding and expression of BPTI in the
bacterial periplasm yielded 8 variants (G12D, A16T, Y35N,
Y35G, F33L, G28W, P13S, and G36D) that are known to be
DTT-sensitive as single amino acid substitutions in vitro
and=or were shown reduce the effective concentration of the
Cys14-Cys38 disulfide, increase the rate constant for its re-
duction, and reduce its stability in vitro by up to 21 kJ=mol
(BPTI Y35G) (2, 17). Five of the DTT-sensitive mutants (G12D,
A16T, Y35N, Y35G, and F33L) have further been shown to
selectively make the Cys14-Cys38 disulfide susceptible to re-
duction by DTT (17). For these variants, it was suggested that
the resulting loss of BPTI activity was due to an increased
flexibility of the BPTI variants and that the mutations might
FIG. 6. Steady-state protein levels of different bla0-BPTI-
0bla variants in vivo correlate well with the corresponding
levels of antibiotic resistance. The relative steady-state
protein levels in whole cell extracts were detected by Wes-
tern blot using an anti-b-lactamase antibody. Band intensities
of b-lactamase (circle) or tripartite fusions containing differ-
ent BPTI variants (filled diamonds) were normalized to the
protein levels of cells expressing bla0-BPTI WT-0bla (open
circle). In the case of bla0-BPTI [14–38]0-bla, the protein level
was determined in whole cell extracts (open diamond) and in
soluble, periplasmic fractions (triangle). In both cases, the
protein level was adjusted to the protein level of bla0-BPTI
WT0-bla in whole cell extracts or the soluble, periplasmic cell
fraction, respectively. The trend line includes the value for
the soluble periplasmic fraction of bla0-BPTI [14–38]0-bla and
excludes the value for the whole cell extract of bla0-BPTI [14–
38]0-bla. Data are expressed as mean values SD.
FIG. 7. Substitution of Cys17 in hG-CSF with serine
leads to an increase in antibiotic resistance as part of the b-
lactamase system.WT hG-CSF, which contains two disulfide
bonds (Cys36-Cys42 and Cys64-Cys74) and one unpaired
cysteine (Cys17), is prone to aggregation, even under native-
like conditions (35). Substitution of the free cysteine with
serine significantly decreases the proteins propensity to ag-
gregate (35). Mid-log phase cells of E. coli MG1655 DampC
expressing bla0-hG-CSF WT-0bla or bla0-hG-CSF C17S-0bla,
respectively, were normalized to OD600 nm¼ 1. Serial dilu-
tions of cultures from 100 to 105 were spotted on LB plates
containing different concentrations of ampicillin. After 18 h
of incubation at 378C, growth or no growth for each dilution
for each ampicillin concentration was determined.
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favor the intramolecular rearrangement of intermediates (2,
17, 18). Altogether, 65% of the BPTI variants obtained in the
in vivo phage selection contain amino acid substitutions that
either destabilize or eliminate the Cys14-Cys38 disulfide bond
in vitro. This is a remarkable overlap, considering that there
are 1102 single amino acid substitutions possible for the BPTI
sequence. The idea that destabilization or removal of Cys14-
Cys38 is key to improving the folding of BPTI in the bacterial
periplasm is further supported by our findings that the level
of antibiotic resistance in the b-lactamase system measured
in vivo directly correlates with the extent of thermodynamic
destabilization of the Cys14-Cys38 disulfide caused by a
given single point mutation in vitro (Fig. 3) and that the rela-
tive protein level of BPTI C14S C38S expressed on its own is
significantly enhanced compared to WT BPTI.
Elimination of the Cys14-Cys38 disulfide might
prevent its unfavorable, early formation of in vivo
That mutations reducing a protein’s in vitro stability lead to
an increase in expression in vivo might appear counterintui-
tive. However, the formation of Cys14-Cys38 is particularly
problematic in BPTI’s in vitro folding pathway due to its early
but nonproductive formation in BPTI folding and its in-
volvement in the rate-limiting step of the overall BPTI folding
reaction (Fig. 8) (6, 46, 49). Due to the high reactivity of Cys14
and Cys38 and the significant conformational preference for
introducing the Cys14-Cys38 disulfide during BPTI refolding
in vitro at neutral pH, the [14–38] intermediate is formedmuch
more rapidly from reduced BPTI than any other species con-
taining a single disulfide bond, native or non-native (1, 8, 9).
Despite this, [14–38] is not a very productive folding inter-
mediate. The vast majority of [14–38] molecules are either
reduced or isomerized before they accumulate in the form of
the more stable single disulfide-bonded species [5–55] and
[30–51] in vitro (41, 45, 46). However, the reduction or isom-
erization of the Cys14-Cys38 disulfide that would allow for
this efficient folding pathway might be more difficult in the
very oxidizing environment of the periplasm (38) than in
in vitro refolding reactions, which tend to be done under less
oxidizing conditions. Importantly, in the absence of other
stabilizing effects such as an additional disulfide bond, the
sole formation of Cys14-Cys38 in reduced BPTI does not
substantially stabilize the native conformation in vitro (12). In
E. coli, BPTI [14–38] does not appear to adopt a soluble, stable
conformation, as reflected by its lowMIC and its accumulation
in the insoluble fraction in the b-lactamase system. Therefore,
the early and rapid formation of Cys14-Cys38 in the periplasm
might favor the accumulation of BPTI in an aggregation prone
state, reducing the number of molecules that can proceed
folding toward [5–55] and [30–51], which are thermodynami-
cally more stable in vitro (1). Consistently, BPTI variants that
mimic single disulfide-bonded intermediates [5–55] and [30–
51] also show an increased protein level compared to [14–38]
in vivo as reflected by their increased MICs in the b-lactamase
system. In fact, the stabilities of BPTI’s native disulfide bonds as
determined in vitro correlate well with the observed antibiotic
resistance of the corresponding tripartite fusions in vivo, sug-
gesting that the b-lactamase system is well suited to assess the
stabilities of different BPTI variants in the living cell.
Elimination of the Cys14-Cys38 disulfide might
further prevent the accumulation of protease-sensitive
intermediates in later stages of BPTI folding
Preventing or decreasing the rapid formation of Cys14-
Cys38 in the early folding of BPTI in vivomight be sufficient to
explain the superior phenotypes of our selected BPTI variants
that eliminated or destabilized this disulfide. However, for-
mation and subsequent reduction of Cys14-Cys38 is also
critical in later folding stages in vitro, which might also help
explain the enhanced antibiotic resistance of tripartite fusions
in which both Cys14 and Cys38 are replaced. At neutral pH, a
large fraction of BPTI molecules accumulates in the form of
the kinetic traps [5–55; 14–38] (N*) or [14–38; 30–51] (N0) (7,
46). For folding to proceed, N* and N0 must reduce Cys14-
Cys38 and unfold substantially to isomerize into the native-
like NHSHSH [5–55; 30–51] (46). The reduction and isomerization
of Cys14-Cys38 appears to be the rate-limiting step in the
productive folding of BPTI in vitro at neutral pH (5, 7). Re-
duction and isomerization of Cys14-Cys38, however, might
be especially problematic in the periplasm, which is high in
oxidase but low in isomerase activity (19).
All the double disulfide-bonded intermediates N*, N0, and
NHSHSH show substantial native-like structure in vitro (39, 42).
However, the amount of native structure in a BPTI interme-
diate and its lifetime under optimized conditions in vitro do
FIG. 8. Consensus folding pathway of WT BPTI in vitro,
modified from Creighton and Goldenberg (7) and Weiss-
man and Kim (8, 45, 46). Starting from fully reduced BPTI
(far left), the [14–38] intermediate is formed much more
rapidly than any other species containing one disulfide-bond
(9). However, the vast majority of [14–38] molecules are ei-
ther reduced or isomerized before they form the thermody-
namically more stable intermediates [30–51] or [5–55] (1).
The most productive folding pathway for BPTI proceeding
from the single disulfide-bonded species occurs via the two
intermediates [5–14; 30–51] and [5–38; 30–51], which are in
rapid equilibrium with each other and contain non-native
disulfides (5, 10). At neutral pH, a large fraction of the BPTI
molecules accumulates as kinetic traps (N0 and N*), which
only slowly isomerize toward the very native-like species
(45, 46). Once NHSHSH is formed, the Cys14-Cys38 disulfide is
introduced rapidly to obtain native BPTI (4). Note that the
relative distribution of the double disulfide-bonded species is
dependent on the pH (10, 45). (For interpretation of the re-
ferences to color in this figure legend, the reader is referred to
the web version of this article at www.liebertonline.com=ars).
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not necessarily indicate the proteolytic sensitivity of that
species in vivo. Although the kinetic trapsN0 andN* persist for
long periods of time under appropriate conditions in vitro (6,
46, 49), the majority of N0 molecules are actually unfolded at
physiological temperatures (7), suggesting that this species
might be prone to proteolysis at 378C in vivo. Of the three
intermediates, NHSHSH is the most stable and native-like species
(4, 44) and is known to fold into its active, native conformation
both in vitro under physiological temperatures and when ex-
pressed in the periplasm of E. coli (28). Although its melting
temperature is about 308C lower than that of WT BPTI, it is
still almost 408C higher than the cultivation temperature of
E. coli, suggesting that NHSHSH is relatively stable in vivo (44). In
good agreement with these findings, the BPTI variant [5–55;
30–51] that represents the NHSHSH species leads to the highest
MIC and protein level among the three double disulfide-
bonded variants tested (Table 2). On the other hand, the two
variants that imitate the kinetically trapped species N* and N0
([5–55; 14–38] and [14–38; 30–51], respectively) exhibit sub-
stantially lower in vivo stabilities, as reflected by decreased
levels of antibiotic resistance and steady-state protein levels in
the b-lactamase system, suggesting that they are proteolyti-
cally more sensitive in vivo.
Because antibiotic resistance is determined by the steady-
state levels of soluble and periplasmic protein, it is possible
that the low MIC values of N* and N0 are caused in part by a
problematic early formation of Cys14-Cys38, inducing pro-
tein aggregation. However, the very good correlation be-
tween antibiotic resistance and protein level in whole cell
extracts for N*, N0, and NHSHSH suggests that aggregation is not
the dominating factor for the decreased MIC of N* and N0
(Table 2). In contrast to [14–38], N* and N0 both possess an
additional, stabilizing disulfide bond, allowing the protein to
reach other, more folded and less aggregation prone confor-
mations. Remarkably, the phenotype conferred by bla0-BPTI
WT-0bla is intermediate (Fig. 4A). This may result from a
mixed population in which somemolecules populate the very
stable, native state (leading to high levels of antibiotic resis-
tance) and other molecules populate the kinetically trapped
intermediate states N* or N0 (leading to low levels of antibiotic
resistance).
In addition to its impact on the early folding events of BPTI,
the elimination or destabilization of Cys14-Cys38 might
therefore also be associated with a simplification of BPTI’s
folding pathway in vivo in later folding stages, in which the
accumulation of the proteolytically sensitive intermediates N*
and N0 is prevented or decreased. Variants that destabilize
Cys14-Cys38 might favor the formation of double disulfide-
bonded species with non-native disulfides, which are more
likely to undergo intramolecular rearrangements and are part
of the most productive folding route of BPTI in vitro, as it has
been already shown for several of the BPTI variants isolated in
our selection (F33L, Y23L, F4L, and Y35L) (50). This might
lead to a preferred formation of the stable and very native-like
species NHSHSH.
Interestingly, in variants of BPTI in which the formation of
the Cys14-Cys38 disulfide bond was prevented, the rate of
formation of native-like BPTI decreased from 9 s1 to
1.6103 s1 at 258C and pH 8.7 in vitro (15). However, this
effect was diminished when experiments were performed at
378C and at a less basic pH (8.3); under these conditions, only
a 3-fold decrease in the overall folding rate for native BPTI
was observed (28). Our finding that BPTI C14S C38S shows
increased protein levels compared to BPTI WT when ex-
pressed in the bacterial periplasm in absence of b-lactamase,
an observation also made by (31), suggests that this slightly
higher rate of formation of the native or native-like protein for
BPTI WT compared to [5–55; 30–51] in vitro cannot, if even
relevant in vivo, compensate for the potentially negative im-
pact of the presence of Cys14-Cys38 in the early and later
folding stages of BPTI in vivo.
The observation that the elimination of a stabilizing dis-
ulfide bond enhances the expression of BPTI might provoke
the questionwhy it was not eliminated by nature in the course
of evolution. However, BPTI variants in which the Cys14-
Cys38 disulfide is eliminated by substituting one or both of
the involved cysteines are known to be cleaved by trypsin up
to 10,000-foldmore rapidly (47) and show decreased secretion
efficiencies in yeast by up to 30% (24), suggesting that Cys14-
Cys38 is important for the in vivo function and protease re-
sistance of the protein.
Dependence of BPTI folding
on the presence of folding factors
Our data suggest that the elimination or reduction of the
kinetic traps N* andN0 in vivomight increase the level of BPTI
in the bacterial periplasm. In BPTI’s natural environment, the
endoplasmatic reticulum, these species are likely to be isom-
erized by the eukaryotic disulfide bond isomerase (protein
disulfide isomerase [PDI]), which has been shown to promote
isomerization of these kinetic traps and enhance the formation
of native BPTI by 27-fold in vitro (48). In fact, co-expression of
rat PDI has been successfully used to increase the expression
of BPTI in E. coli (32). Compared to its eukaryotic counterpart
PDI, the isomerase activity of the bacterial enzyme responsi-
ble for disulfide bond isomerization in the periplasm, DsbC, is
relatively low (37). Consistent with that, we did not find the
level of antibiotic resistance conferred by various BPTI tri-
partite fusions to be strongly dependent on the presence of
native levels of DsbC (data not shown). BPTI folding in E. coli,
however, severely depends on the activity of the disulfide
bond oxidase DsbA (33). The importance of DsbA for BPTI
folding is supported by our finding that dsbA strains ex-
pressing different bla-BPTI fusions showed decreased levels
of antibiotic resistance compared to a dsbAþ strain (data not
shown).
Conclusion
Presumably due to the differences in the redox-environment
of the endoplasmatic reticulum and the bacterial periplasm,
the heterologous expression of disulfide-rich, heterologous
proteins in E. coli is often very challenging (32). Our results for
BPTI and hG-CSF indicate that our tripartite fusion systems
are well suited to enhance expression and folding of difficult
to express heterologous proteins in the bacterial periplasm by
randommutation of the target gene and a simple selection for
improved phenotypes in our systems. The feasibility of our
approach is supported by the good correlation between the
relative level of antibiotic resistance and the relative level of
the tripartite fusion in the b-lactamase system (Fig. 6) and the
enhanced protein levels of selected BPTI variants compared to
BPTI WT (determined for double mutant C14S C38S and
single mutants K26M and G28W) in absence of b-lactamase
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we observe. Further, the majority of variants selected for
increased expression of BPTI eliminates or destabilizes the
Cys14-Cys38 disulfide bond, suggesting that circumvention
of Cys14-Cys38-related folding problems in early or later
folding stagesmay improve the expression of BPTI in vivo and
compensate for the apparent loss in stability in vitro. For
proteins with unpaired cysteines like hG-CSF, our systems
can be used to easily identify if and how free cysteines can be
substituted to increase expression and in vivo stability of the
protein. Our results therefore emphasize the power of ge-
netic selection to identify and circumvent critical steps and
residues problematic for in the in vivo folding pathway of
proteins without the need to perform time-consuming site-
directed mutagenesis experiments. Although we used an
extremely well-studied model protein here, this technique
should be applicable to a variety of target proteins with
potentially unknown folding pathways. In cases where an
unmutagenized target protein is preferred, our selection
systems also provide the convenient possibility of fine-
tuning the redox-environment of the periplasm for the
enhanced expression of a target protein by mutating co-
expressed folding factors such as oxidoreductases or pro-
teins involved in redox-maintenance.
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Abbreviations Used
BPTI¼ bovine pancreatic trypsin inhibitor
DTT¼dithiothreitol
hG-CSF¼human granulocyte-colony stimulating factor
LB¼ lysogeny broth, also known as
Luria-Bertani broth
MIC¼minimal inhibitory concentration
PCR¼polymerase chain reaction
PDI¼protein disulfide isomerase
pfu¼plaque forming unit
PROSIDE¼protein stability increased by directed
evolution
SD¼ standard deviation
WT¼wild-type
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